FDA Approves Lymphir for R/R Cutaneous T-Cell LymphomaAugust 9, 2024T Cell LymphomasPatient & Survivor CareBusiness of Medicine
Immunotherapy May Be Overused in Dying Patients With CancerAugust 8, 2024DLBCLMixed TopicsPatient & Survivor CarePediatricsAggressive LymphomasALLAML
FDA Approves First Engineered Cell Therapy for a Solid TumorAugust 2, 2024Patient & Survivor CareBusiness of Medicine
FDA Expands Darzalex Faspro Indication in MyelomaAugust 2, 2024Multiple MyelomaPatient & Survivor CareBusiness of Medicine
The Last 30 Days: How Oncologists’ Choices Affect End-of-Life Cancer CareAugust 2, 2024Patient & Survivor CareDLBCLMixed Topics
FDA Calls AstraZeneca’s NSCLC Trial Design Into QuestionJuly 30, 2024Business of MedicinePatient & Survivor Care
Greater Transparency of Oncologists’ Pharma Relationships NeededJuly 22, 2024Patient & Survivor CareDLBCLDiversity in MedicineMixed TopicsAggressive LymphomasALLAML
